Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit

被引:40
|
作者
Khakwani, A. [1 ]
Rich, A. L. [2 ]
Powell, H. A. [1 ,3 ]
Tata, L. J. [1 ]
Stanley, R. A. [4 ]
Baldwin, D. R. [2 ]
Duffy, J. P. [5 ]
Hubbard, R. B. [1 ,3 ]
机构
[1] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England
[2] Univ Nottingham Hosp, Dept Resp Med, Nottingham NG5 1PB, England
[3] Univ Nottingham, Nottingham Resp Res Unit, Nottingham NG5 1PB, England
[4] Hlth & Social Care Informat Ctr, Clin Audit Support Unit, Leeds LS1 6AE, W Yorkshire, England
[5] Univ Nottingham Hosp, Dept Thorac Surg, Nottingham NG5 1PB, England
关键词
lung neoplasm; survival; thoracic surgery; England; SURGICAL RESECTION; UK; MANAGEMENT; SWEDEN;
D O I
10.1038/bjc.2013.572
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In comparison with other European and North American countries, England has poor survival figures for lung cancer. Our aim was to evaluate the changes in survival since the introduction of the National Lung Cancer Audit (NLCA). Methods: We used data from the NLCA to identify people with non-small-cell lung cancer (NSCLC) and stratified people according to their performance status (PS) and clinical stage. Using Cox regression, we calculated hazard ratios (HRs) for death according to the year of diagnosis from 2004/2005 to 2010; adjusted for patient features including age, sex and co-morbidity. We also assessed whether any changes in survival were explained by the changes in surgical resection rates or histological subtype. Results: In this cohort of 120 745 patients, the overall median survival did not change; but there was a 1% annual improvement in survival over the study period (adjusted HR 0.99, 95% confidence interval (CI) 0.98-0.99). Survival improvement was only seen in patients with good PS and early stage (adjusted HR 0.97, 95% CI 0.95-0.99) and this was partly accounted for by changes in resection rates. Conclusion: Survival has only improved for a limited group of people with NSCLC and increasing surgical resection rates appeared to explain some of this improvement.
引用
收藏
页码:2058 / 2065
页数:8
相关论文
共 50 条
  • [31] Area-based disparities in non-small-cell lung cancer survival
    Paakkola, Nelly-Maria
    Jekunen, Antti
    Sihvo, Eero
    Johansson, Mikael
    Andersen, Heidi
    ACTA ONCOLOGICA, 2024, 63 (01) : 146 - 153
  • [32] Prognostic nomogram for predicting survival of non-small-cell lung cancer patients
    Ryu, Jeong Seon
    Yi, Bo-Rim
    Kim, Jung Soo
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S40 - S40
  • [33] Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer
    Morris, Zachary S.
    Cannon, Donald M.
    Morris, Brett A.
    Bentzen, Soren M.
    Kozak, Kevin R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) : 1608 - 1615
  • [34] Erlotinib extends survival of patients with relapsed non-small-cell lung cancer
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (08): : 1077 - 1077
  • [35] Imaging surveillance and survival for surgically resected non-small-cell lung cancer
    Backhus, Leah M.
    Farjah, Farhood
    Liang, Chao-Kang Jason
    He, Hao
    Varghese, Thomas K., Jr.
    Au, David H.
    Flum, David R.
    Zeliadt, Steven B.
    JOURNAL OF SURGICAL RESEARCH, 2016, 200 (01) : 171 - 176
  • [36] Do molecular markers predict survival in non-small-cell lung cancer?
    Greatens, TM
    Niehans, GA
    Rubins, JB
    Jessurun, J
    Kratzke, RA
    Maddaus, MA
    Niewoehner, DE
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (04) : 1093 - 1097
  • [37] Midterm survival of imaging-assisted robotic lung segmentectomy for non-small-cell lung cancer
    Chaari, Zied
    Montagne, Francois
    Sarsam, Matthieu
    Bottet, Benjamin
    Rinieri, Philippe
    Gillibert, Andre
    Baste, Jean Marc
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (06) : 1016 - 1023
  • [38] Cancer vaccines for non-small-cell lung cancer
    Palma, M.
    Choudhury, A.
    Mellstedt, H.
    MINERVA CHIRURGICA, 2009, 64 (06) : 643 - 653
  • [39] Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC).
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer
    Alexander, Marliese
    Wolfe, Rory
    Ball, David
    Conron, Matthew
    Stirling, Robert G.
    Solomon, Benjamin
    MacManus, Michael
    Officer, Ann
    Karnam, Sameer
    Burbury, Kate
    Evans, Sue M.
    BRITISH JOURNAL OF CANCER, 2017, 117 (05) : 744 - 751